Cargando…
Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines
The emergence of nanotechnology as a key enabling technology over the past years has opened avenues for new and innovative applications in nanomedicine. From the business aspect, the nanomedicine market was estimated to worth USD 293.1 billion by 2022 with a perception of market growth to USD 350.8...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802788/ https://www.ncbi.nlm.nih.gov/pubmed/33447033 http://dx.doi.org/10.2147/IJN.S288236 |
_version_ | 1783635815376617472 |
---|---|
author | Albalawi, Fahad Hussein, Mohd Zobir Fakurazi, Sharida Masarudin, Mas Jaffri |
author_facet | Albalawi, Fahad Hussein, Mohd Zobir Fakurazi, Sharida Masarudin, Mas Jaffri |
author_sort | Albalawi, Fahad |
collection | PubMed |
description | The emergence of nanotechnology as a key enabling technology over the past years has opened avenues for new and innovative applications in nanomedicine. From the business aspect, the nanomedicine market was estimated to worth USD 293.1 billion by 2022 with a perception of market growth to USD 350.8 billion in 2025. Despite these opportunities, the underlying challenges for the future of engineered nanomaterials (ENMs) in nanomedicine research became a significant obstacle in bringing ENMs into clinical stages. These challenges include the capability to design bias-free methods in evaluating ENMs’ toxicity due to the lack of suitable detection and inconsistent characterization techniques. Therefore, in this literature review, the state-of-the-art of engineered nanomaterials in nanomedicine, their toxicology issues, the working framework in developing a toxicology benchmark and technical characterization techniques in determining the toxicity of ENMs from the reported literature are explored. |
format | Online Article Text |
id | pubmed-7802788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78027882021-01-13 Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines Albalawi, Fahad Hussein, Mohd Zobir Fakurazi, Sharida Masarudin, Mas Jaffri Int J Nanomedicine Review The emergence of nanotechnology as a key enabling technology over the past years has opened avenues for new and innovative applications in nanomedicine. From the business aspect, the nanomedicine market was estimated to worth USD 293.1 billion by 2022 with a perception of market growth to USD 350.8 billion in 2025. Despite these opportunities, the underlying challenges for the future of engineered nanomaterials (ENMs) in nanomedicine research became a significant obstacle in bringing ENMs into clinical stages. These challenges include the capability to design bias-free methods in evaluating ENMs’ toxicity due to the lack of suitable detection and inconsistent characterization techniques. Therefore, in this literature review, the state-of-the-art of engineered nanomaterials in nanomedicine, their toxicology issues, the working framework in developing a toxicology benchmark and technical characterization techniques in determining the toxicity of ENMs from the reported literature are explored. Dove 2021-01-08 /pmc/articles/PMC7802788/ /pubmed/33447033 http://dx.doi.org/10.2147/IJN.S288236 Text en © 2021 Albalawi et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Albalawi, Fahad Hussein, Mohd Zobir Fakurazi, Sharida Masarudin, Mas Jaffri Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines |
title | Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines |
title_full | Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines |
title_fullStr | Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines |
title_full_unstemmed | Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines |
title_short | Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines |
title_sort | engineered nanomaterials: the challenges and opportunities for nanomedicines |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802788/ https://www.ncbi.nlm.nih.gov/pubmed/33447033 http://dx.doi.org/10.2147/IJN.S288236 |
work_keys_str_mv | AT albalawifahad engineerednanomaterialsthechallengesandopportunitiesfornanomedicines AT husseinmohdzobir engineerednanomaterialsthechallengesandopportunitiesfornanomedicines AT fakurazisharida engineerednanomaterialsthechallengesandopportunitiesfornanomedicines AT masarudinmasjaffri engineerednanomaterialsthechallengesandopportunitiesfornanomedicines |